Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.79 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317301 | 0.90 | MAPT (0.81) | MAPTALDH1A1GPR174SMN1; SMN2LMNA | |
| SCHEMBL22621220 | 0.87 | GPR174 (1.00) | MAPTALDH1A1GPR174SMN1; SMN2LMNA | |
| SCHEMBL3315404 | 0.87 | MAPT (0.72) | MAPTALDH1A1GPR174SMN1; SMN2LMNA | |
| SCHEMBL22621283 | 0.84 | GPR174 (1.00) | MAPTALDH1A1GPR174LMNAGAA | |
| SCHEMBL31739514 | 0.84 | MAPT (0.67) | MAPTALDH1A1GPR174SMN1; SMN2LMNA | |
| SCHEMBL30258446 | 0.83 | MAPT (0.63) | MAPTALDH1A1GPR174SMN1; SMN2LMNA | |
| SCHEMBL521293 | 0.83 | MAPT (0.63) | MAPTALDH1A1GPR174SMN1; SMN2LMNA | |
| SCHEMBL9302533 | 0.83 | GPR174 (0.67) | MAPTALDH1A1GPR174SMN1; SMN2LMNA | |
| SCHEMBL29847854 | 0.82 | MAPT (0.76) | MAPTALDH1A1GPR174SMN1; SMN2LMNA | |
| SCHEMBL16513593 | 0.82 | MAPT (0.76) | MAPTALDH1A1GPR174SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | MAPT 2130/4885ALDH1A1 649/4885GPR174 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.